Company intelligence / Profile preview

QLT USA

Fort Collins, Colorado, United States

Ownership: Private
Development stage: Other

Overview

QLT USA was a biopharmaceutical company based in Fort Collins, Colorado, primarily known for its proprietary Atrigel drug delivery technology. The company was formed following the 2004 acquisition of Atrix Laboratories by the Canadian biotech firm QLT Inc. Its lead commercial product was Eligard (leuprolide acetate), a treatment for advanced prostate cancer that utilizes the Atrigel system for sustained release. In 2009, QLT Inc. sold the QLT USA subsidiary and its Fort Collins operations to Tolmar Holding, Inc., which continues to manufacture and develop products based on the acquired technology.

Therapeutic areas: Infectious DiseasesOncologyDermatology
Modalities: Small moleculeDrug delivery system
Industry: Biotech

Partnerships

Sanofi-AventisAstellas Pharma

Beyond the preview

Go deeper on QLT USA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLT USA.

Explore the full profile